Name: 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition (Time Zone - EST)
Start: 2021-06-28
End: 2021-07-01

CONFERENCE AGENDA

Registration	10:15 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening Remarks from the Chairman Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	10:55 - 11:00
Keynote Presentation: PD-1 Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy	11:00 - 11:30
NEXT GEN ANTIBODIES, PRE-CLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY DEVELOPMENTS
Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine Christelle Johnson, Senior Field Applications Scientist, Personalis	11:30 - 12:00
Antibody Fragment Drug-Conjugates (FDCs): Application of ANT-043 and ANT-045 in solid tumors Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	12:00 - 12:30
Selective Tumor Treg Depletion with a Bispecific Antibody Bonnie Hammer, Vice President, Research & Development, Invenra	12:30 - 13:00
Networking and One-on-One Meetings on the event portal	13:00 - 13:15
Evaluating treatment effect in clinical trials in immuno-oncology Tomasz Burzykowski, Vice President, Research, IDDI	13:15 - 13:45
Using Systems Pharmacology Modeling to Design and Optimize Biotherapeutics from Development to the Clinic John Burke, CEO, Co-Founder, President, Applied BioMath	13:45 - 14:15
Tumor-targeted costimulatory trimerbodies for cancer immunotherapy Juan Perez Villar, CEO, LeadArtis	14:15 - 14:45
Autologous Personalized Tumor Cell-Based Immunotherapy IGV-001 Exploiting IGF1R Antisense Molecule Produces Durable Responses in Glioblastoma Patients and in a Variety of Animal Models Mark Exley, Chief Scientific Officer, ImVax	14:45 - 15:15
Closing Remarks from Chairman	15:15 - 15:20
End of Day 1 and One-one-One Networking	15:20 - 15:20

Registration	10:15 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening remarks from the Chairman Maurizio Chiriva-Internati, Chairman, CEO, Kiromic	10:55 - 11:00
Keynote presentation: Personalized, off-the-shelf cellular immunotherapy for cancer William Williams, President, CEO, Briacell Therapeutics Corporation	11:00 - 11:30
CELLULAR THERAPY, PERSONALIZED IMMUNOTHERAPY, VACCINES AND ONCOLYTIC VIRAL THERAPY
Mesothelin isoform 2 is a novel target for allogenic CAR γδT cell therapy in solid tumors Maurizio Chiriva-Internati, Chairman, CEO, Kiromic	11:30 - 12:00
Precision Pathology enabled by Multiplexed Immunofluorescence Keith Wharton, VP, Medical Director, Ultivue, USA	12:00 - 12:30
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA	12:30 - 13:00
Networking and One-on-One Meetings on the event portal	13:00 - 13:15
Novel bispecific γδ T cell engagers for the treatment of cancer Paul Parren, EVP and Head of R&D, Lava Therapeutics	13:15 - 13:45
Use of natural T cell activation represents next step forward in developing next generation of T cell therapy products Paul Lammers, President & CEO, Triumvira Immunologics	13:45 - 14:15
Clinical efficacy and immuno-modualtory properties of oncolytic adenovirus ONCOS-102 Victor Levitsky, Chief Scientific Officer, Targovax	14:15 - 14:45
Differentiating tumor-specific PD-1+TCF-1+ stem-like resource CD8 T cells towards a distinct effector T cell population through PD-1 mediated delivery of IL-2v Laura Codarri Deak, Principal Scientist, Team Leader, Cancer Immunotherapy, Roche	14:45 - 15:15
Utilization of HMGN1, an Th1-polarizing alarmin, for effective antitumor immunotherapies De Yang, Staff Scientist, NIH, National Cancer Institute, Center for Cancer Research	15:15 - 15:45
Closing Remarks from Chairman	15:45 - 15:50
End of Day 2 and One-one-One Networking	15:50 - 15:50

Registration	10:15 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening remarks from the Chairman Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	10:55 - 11:00
IMMUNE CHECKPOINT INHIBITORS & COMBINATION STRATEGIES
Genomic Profiling for IO Clinical Trials including Blood-Based Tumor Mutational Burden (bTMB) Reed Selby, Director of Biopharma Business Development, Predicine	11:30 - 12:00
Humanized Immune Checkpoint Mice Improve Translatability of Novel Immunotherapies Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen	12:00 - 12:30
Reshaping the immune tumor microenvironment through TNF blockade Roxana Schillaci, Principal Researcher, Argentina National Council of Scientific Research	12:30 - 13:00
Networking and One-on-One Meetings on the event portal	13:00 - 13:15
ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage Héctor Pérez Montoyo, Director, Biological Research, Ability Pharma	13:15 - 13:45
Therapy of advanced non melanoma skin cancers (NMSC) with ICI: What are the advantages and why? Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	13:45 - 14:15
Peptide therapeutics as combination strategy with immune checkpoint inhibitors Helena Kiefel, Program Leader, Immuno-Oncology, Second Genome	14:15 - 14:45
Combination Immune therapy: Immune cell as a delivery vehicle and a co-effector oncolytic virus Pamela Reilly Contag, CEO, BioEclipse Therapeutics	14:45 - 15:15
Closing Remarks from Chairman	15:15 - 15:20
End of Day 3 and One-one-One Networking	15:20 - 15:20

Registration	10:15 - 10:50
Welcome note from MarketsandMarkets	10:50 - 10:55
Opening remarks from the Chairman Héctor Pérez Montoyo, Director, Biological Research, Ability Pharma	10:55 - 11:00
Valo Therapeutics - Unique cancer and anti-infective immunotherapy platforms Sari Pesonen, Co-Founder, Head, R&D, Valo Therapeutics	11:00 - 11:30
The role of AXL in immuno-oncology: A translational perspective Hani Gabra , Co-Founder/ Chief Scientific Officer, Papyrus Therapeutics	11:30 - 12:00
Technologies That Matter: Digital Pathology, Multiplexed IHC and AI Steven Lynum, Executive Director Global Business Development, PHC Corporation	12:00 - 12:30
DSP107, a first-in-class CD47x41BB targeting fusion protein, activates both – innate and adaptive immunity Yaron Pereg, CEO, KAHR Bio	12:30 - 13:00
Networking and One-on-One Meetings on the event portal	13:00 - 13:15
Humanized Mouse Models for Immuno-Oncology Research Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices	13:15 - 13:45
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Jessica McDonough, Co-Founder, Attivare Therapeutics	13:45 - 14:15
Closing Remarks from Chairman	14:15 - 14:20
End of Conference and One-one-One Networking on Event Portal	14:20 - 14:20